Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Singh, Indrajeet
Sathe, Abhishek G.
Singh, Pratap
Diderichsen, Paul M.
Fauchet, Floris
Maringwa, John
Pierrillas, Philippe
Phan, See-Chun
Girish, Sandhya
Othman, Ahmed A.
机构：
[1] Gilead Sci Inc, Foster City, CA USA
[2] Certara USA Inc, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1076
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
    Bardia, Aditya
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Oliveira, Mafalda
    Rugo, Hope S.
    Brufsky, Adam
    Kalinsky, Kevin
    Cortes, Javier
    O'Shaughnessy, Joyce
    Dieras, Veronique C.
    Carey, Lisa A.
    Gianni, Luca
    Piccart-Gebhart, Martine J.
    Loibl, Sibylle
    Zhu, Yanni
    Phan, See-Chun
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Spring, Laura M.
    Nakajima, Erika
    Hutchinson, Jennifer
    Viscosi, Elene
    Blouin, Gayle
    Weekes, Colin
    Rugo, Hope
    Moy, Beverly
    Bardia, Aditya
    ONCOLOGIST, 2021, 26 (10): : 827 - 834
  • [43] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
  • [44] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
  • [45] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [46] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [48] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [49] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 8, 98, 2022)
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2024, 10 (01)
  • [50] Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1-metastatic triple-negative breast cancer (mTNBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Yam, Clinton
    Daniel, Brooke R.
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345